Publications

Dupuis N, Laschet C, Franssen D, Szpakowska M, Gilissen J, Geubelle P, Soni A, Parent AS, Pirotte B, Chevigne A, Twizere JC, Hanson J.
Activation of the orphan G protein-coupled receptor GPR27 by surrogate ligands promotes β-arrestin 2 recruitment.
Mol Pharmacol. 2017, in press. doi: 10.1124/mol.116.107714. 
PMID: 28314853

Geubelle P, Gilissen J, Dilly S, Poma L, Dupuis N, Laschet C, Abboud D, Inoue A, Jouret F, Pirotte B, Hanson J.
Identification and pharmacological characterization of succinate receptor agonists.
British Journal of Pharmacology. 2017, in press. doi: 10.1111/bph.13738.
PMID: 28160606

Abboud D, Hanson J.
Chemokine neutralization as an innovative therapeutic strategy for atopic dermatitis.
Drug Discov Today. 2016, in press. doi: 10.1016/j.drudis.2016.11.023. Review.
PMID: 27956056

Hanson J, Chevigné A.
GPCRs in immunity: Atypical receptors and novel concepts.
Biochemical Pharmacology. 2016 Aug 15;114:1-2. doi: 10.1016/j.bcp.2016.06.017. 
PMID: 27372602

Szpakowska M, Dupuis N, Baragli A, Counson M, Hanson J, Piette J, Chevigné A.
Human herpesvirus 8-encoded chemokine vCCL2/vMIP-II is an agonist of the atypical chemokine receptor ACKR3/CXCR7.
Biochemical Pharmacology. 2016 Aug 15;114:14-21. doi: 10.1016/j.bcp.2016.05.012.
PMID: 27238288

Gilissen J, Jouret F, Pirotte B, Hanson J.
Insight into SUCNR1 (GPR91) structure and function.
Pharmacology and Therapeutics. 2016, Mar;159:56-65. doi: 10.1016/j.pharmthera.2016.01.008.  Review.
PMID: 26808164

Gilissen J, Geubelle P, Dupuis N, Laschet C, Pirotte B, Hanson J.
Forskolin-free cAMP assay for Gi-coupled receptors
Biochemical Pharmacology. 2015, Dec 1;98(3):381-91. doi: 10.1016/j.bcp.2015.09.010

Bambi-Nyanguile SM, Hanson J, Ooms A, Alpan L, Kolh P, Dogné JM, Pirotte B.
Synthesis and pharmacological evaluation of 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as novel thromboxane A₂ receptor antagonists.
European Journal of Medicinal Chemistry. 2013, Jul; 65:32-40. doi: 10.1016/j.ejmech.2013.04.033.

Hanson J, Ferreirós N, Pirotte B, Geisslinger G, Offermanns S.
Heterologously expressed formyl peptide receptor 2 (FPR2/ALX) does not respond to lipoxin A₄.
Biochemical Pharmacology. 2013, Jun 15;85(12):1795-802. doi: 10.1016/j.bcp.2013.04.019.

Hanson J, Gille A, Offermanns S.
Role of HCA₂ (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin.
Pharmacology & Therapeutics. 2012, Oct;136(1):1-7. doi: 10.1016/j.pharmthera.2012.06.003.

Lukasova M, Hanson J, Tunaru S, Offermanns S.
Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials.
Trends in Pharmacological Sciences. 2011, Dec;32(12):700-7. doi: 10.1016/j.tips.2011.08.002.

Cherdon C, Rolin S, Hanson J, Ooms A, de Leval L, Drion P, Michiels C, Pirotte B, Masereel B, Sakalihassan N, Defraigne JO, Dogné JM.
BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase.
Prostaglandins Other Lipid Mediat. 2011, Apr;94(3-4):124-32. doi: 10.1016/j.prostaglandins.2011.03.001.

Hanson J, Gille A, Zwykiel S, Lukasova M, Clausen BE, Ahmed K, Tunaru S, Wirth A, Offermanns S.
Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice.
Journal of Clinical Investigation. 2010 Aug;120(8):2910-9. doi: 10.1172/JCI42273.

Ahmed K, Tunaru S, Tang C, Müller M, Gille A, Sassmann A, Hanson J, Offermanns S.
An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81.
Cell Metab. 2010, Apr 7;11(4):311-9. doi: 10.1016/j.cmet.2010.02.012.

Ahmed K, Tunaru S, Langhans CD, Hanson J, Michalski CW, Kölker S, Jones PM, Okun JG, Offermanns S.
Deorphanization of GPR109B as a receptor for the beta-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis.
J Biol Chem. 2009, Aug 14;284(33):21928-33. doi: 10.1074/jbc.M109.019455.

Hanson J, Dogné JM, Ghiotto J, Moray AL, Kinsella BT, Pirotte B. Design,
synthesis, and SAR study of a series of N-alkyl-N'-[2-(aryloxy)-5-nitrobenzenesulfonyl]ureas and -cyanoguanidine as selective antagonists of the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor.
Journal of Medicinal Chemistry. 2007, Aug 9;50(16):3928-36.

Lanoye L, Segers P, Tchana-Sato V, Rolin S, Dogne JM, Ghuysen A, Lambermont B, Hanson J, Desaive T, Verdonck P, D'Orio V, Kolh P.
Cardiovascular haemodynamics and ventriculo-arterial coupling in an acute pig model of coronary ischaemia-reperfusion.
Experimental Physiology. 2007, Jan;92(1):127-37.

Hanson J, Reynaud D, Qiao N, Devel P, Moray AL, Renard JF, Kelley LP, Winum JY, Montero JL, Kinsella BT, Pirotte B, Pace-Asciak CR, Dogné JM.
Synthesis and pharmacological evaluation of novel nitrobenzenic thromboxane modulators as antiplatelet agents acting on both the alpha and beta isoforms of the human thromboxane receptor.
Journal of Medicinal Chemistry. 2006, Jun 15;49(12):3701-9.

Dogné JM, Hanson J, Supuran C, Pratico D.
Coxibs and cardiovascular side-effects: from light to shadow.
Current Pharmaceutical Design. 2006, 12(8):971-5.

Dogné JM, Hanson J, de Leval X, Pratico D, Pace-Asciak CR, Drion P, Pirotte B, Ruan KH.
From the design to the clinical application of thromboxane modulators.
Current Pharmaceutical Design. 2006, 12(8):903-23.

Kolh P, Rolin S, Tchana-Sato V, Pétein M, Ghuysen A, Lambermont B, Hanson J, Magis D, Segers P, Masereel B, D'Orio V, Dogne JM.
Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion.
Prostaglandins & Other Lipid Mediators.  2006, Mar;79(1-2):53-73.

Tchana-Sato V, Dogné JM, Lambermont B, Ghuysen A, Magis D, Morimont P, Hanson J, D'Orio V, Limet R, Kolh P.
Effects of BM-573, a thromboxane A2 modulator on systemic hemodynamics perturbations induced by U-46619 in the pig.
Prostaglandins & Other Lipid Mediators. 2005, Dec;78(1-4):82-95.

Dogné JM, Hanson J, Pratico D.
Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis.
Trends in Pharmacological Sciences. 2005, Dec;26(12):639-44.

Dogné JM, Rolin S, Pétein M, Tchana-Sato V, Ghuysen A, Lambermont B, Hanson J, Magis D, Segers P, Pirotte B, Masereel B, Drion P, D'Orio V, Kolh P.
Characterization of an original model of myocardial infarction provoked by coronary artery thrombosis induced by ferric chloride in pig.
Thrombosis Research. 2005, 116(5):431-42.

Ghuysen A, Dogné JM, Chiap P, Rolin S, Masereel B, Lambermont B, Kolh P, Tchana-Sato V, Hanson J, D'Orio V.
Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor.
Cardiovascular Drug Review. 2005,  23(1):1-14.

Kolh P, Lambermont B, Ghuysen A, Tchana-Sato V, Dogne JM, Hanson J, Gerard P, D'Orio V, Pierard L, Limet R.
Effects of dobutamine on left ventriculoarterial coupling and mechanical efficiency in acutely ischemic pigs.
Journal of Cardiovascular Pharmacology. 2005, 45(2):144-52.

Hanson J, Rolin S, Reynaud D, Qiao N, Kelley LP, Reid HM, Valentin F, Tippins J, Kinsella BT, Masereel B, Pace-Asciak C, Pirotte B, Dogné JM.
In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
Journal of Pharmacology and Experimental Therapeutics. 2005, 313(1):293-301.

Hanson J, de Leval X, David JL, Supuran C, Pirotte B, Dogné JM.
Progress in the field of GPIIb/IIIa antagonists.
Current Medicinal Chemistry: Cardiovascular and Hematology Agents. 2004, 2(2):157-67

Dogné JM, Hanson J, de Leval X, Masereel B, Kolh P, Pirotte B.
New developments on thromboxane modulators.
Mini Reviews in Medicinal Chemistry. 2004, 4(6):649-57.

de Leval X, Hanson J, David JL, Masereel B, Pirotte B, Dogné JM.
New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators.
Current Medicinal Chemistry. 2004, 11(10):1243-52

Dogné JM, de Leval X, Hanson J, Frederich M, Lambermont B, Ghuysen A, Casini
A, Masereel B, Ruan KH, Pirotte B, Kolh P. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators.
Curr Med Chem. 2004May;11(10):1223-41. Review. PubMed PMID: 15134516.

Ghuysen A, Lambermont B, Dogné JM, Kolh P, Tchana-Sato V, Morimont P, Magis D, Hanson J, Segers P, D'Orio V. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism.
J Pharmacol Exp Ther. 2004 Sep;310(3):964-72.Epub 2004 Apr 30. PubMed PMID: 15121765.

Dogné JM, Hanson J, de Leval X, Kolh P, Tchana-Sato V, de Leval L, Rolin S, Ghuysen A, Segers P, Lambermont B, Masereel B, Pirotte B.
Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.
J Pharmacol Exp Ther. 2004 May;309(2):498-505. Epub 2004 Jan 23. PubMed PMID: 14742735